NDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEOCILLIN (carbenicillin indanyl sodium) is an oral penicillin antibiotic approved in 1972 for urinary tract and prostate infections. It is a broad-spectrum beta-lactam that inhibits bacterial cell wall synthesis. The drug is primarily used for chronic or recurrent urinary tract infections in patients who require prolonged oral antimicrobial therapy.
LOE Approaching
This legacy product faces imminent loss of exclusivity with minimal current market activity; brand teams are likely in maintenance mode with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GEOCILLIN offers minimal career advancement opportunity; linked job count is zero, reflecting the product's late-lifecycle status. Working on this asset typically involves defensive commercial strategies, generic management, and maintenance of legacy market share rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on GEOCILLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.